
Announcing the InnovateTB contest! Innovations are revolutionizing TB. Tell us your story! On World TB Day, the Stop TB Partnership Working Group on New TB Drugs (WGND) announces the InnovateTB Contest to encourage and highlight innovations to achieve zero deaths from TB in this generation. We are inviting interested participants to take two simple steps: [...]
The Stop TB Partnership has issued a Call to Action on Childhood TB. The call was an outcome of an international meeting organized jointly by the European Centre for Disease Prevention and Control (ECDC) and the Stop TB Partnership’s Childhood TB Subgroup in March. There was strong consensus among participants on the urgent need to make the voice of children heard through concerted advocacy efforts. Links are provided to information on the Call to Action and to a page where you can sign the Call to Action on Childhood TB. There are also links to previous coverage by the WGND on topics related to Childhood TB.
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. This is part two of our interview with him.
The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.